Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
Nexgel Inc (NXGL) specializes in advanced hydrogel solutions for medical, cosmetic, and diagnostic applications through proprietary electron beam cross-linking technology. This page provides centralized access to official corporate announcements and strategic developments.
Investors and industry professionals will find verified updates including earnings reports, product launch details, regulatory milestones, and partnership announcements. Our curated news collection enables efficient tracking of NXGL's innovations in transdermal drug delivery systems and FDA-approved wound care solutions.
Key content categories include:
- Financial performance updates and SEC filings
- New hydrogel product releases across medical and consumer markets
- Manufacturing process innovations and patent developments
- Strategic collaborations in healthcare and cosmetics sectors
Bookmark this page for real-time access to NXGL's corporate communications and market-moving announcements. For comprehensive analysis of hydrogel industry trends, visit Stock Titan's research portal regularly.
NEXGEL reported a 32% year-over-year revenue increase, reaching $2.05 million for 2022, driven by 34.7% growth in contract manufacturing and a 67.0% rise in branded consumer products. By year-end, the company had over $6.6 million in cash and securities, ensuring operational stability through 2025. Despite a slight revenue dip in Q4 2022, NEXGEL launched innovative products like Turfguard and expanded its joint ventures. The gross profit margin improved significantly to approximately 12.5%, a 3,100% increase from the previous year. However, a net loss of $4.75 million was reported for 2022, with expectations of reduced interest expenses in the coming year.
FAQ
What is the current stock price of Nexgel (NXGL)?
What is the market cap of Nexgel (NXGL)?
